Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Prescribes Capital (China)

This article was originally published in PharmAsia News

Executive Summary

Lilly Asian Ventures, a $35 million venture capital fund spun off from Eli Lilly & Co.'s Lilly Ventures, will provide capital to health care projects in Asia. Its first investment of $10 million went to Bio Veda China, a Shanghai-based venture capital firm that is looking to raise $100 million. The investment "is helping to seed the growth of China's life sciences industry," according to Lilly President and COO John Lechleiter. In 2006, the National Development and Reform Commission says output from China's biotechnology industry surged 22 percent from the prior year to 42 billion yuan (US$5.38 billion). (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts